Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Arcus Biosciences (NYSE:RCUS) and maintained a $30 price target.
August 09, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Arcus Biosciences and maintained a $30 price target.
The reiteration of an Outperform rating and a maintained price target of $30 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100